

## Disclosure Form Pertaining to ADA Editorial Activities International Committee of Medical Journal Editors (ICMJE) Adapted by the American Diabetes Association

Date:	2/13/2024
Name:	Thomas Danne
Journal Title:	Diabetes Care

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to your role as editor for the above-titled journal. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The relationships/activities/interests of the editors should be defined broadly. For example, if you are asked to oversee the peer-review of manuscripts pertaining to the epidemiology of diabetes, you should declare all relationships with manufacturers of glucose-lowering medications.

This form was modified by the American Diabetes Association (ADA) in December 2023 to pertain to editorial review activities for ADA professional publications. The original disclosure form developed by the International Committee of Medical Journal Editors (ICMJE) can be found at <a href="https://www.icmje.org/disclosure-of-interest">https://www.icmje.org/disclosure-of-interest</a>.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	Funding support for research projects completed or awarded in	None			
	the past 36 months (including provision of study materials, article processing charges, etc.)	AstraZeneca, Lilly, Boehringer, NovoNordisk, Sanofi	Institution		
			Click the tab key to add additional rows.		
	1	1	Continues on the next page		



		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
			Click the tab key to add additional rows.		
3	Royalties or licenses	None			
			Click the tab key to add additional rows.		
4	Consulting fees	□ None			
		Vitalaire, Vertex	Personal Compensation		
			Click the tab key to add additional rows.		
5 Payment or honoraria for					
	speakers bureaus, manuscript writing or educational events	Abbott, Bayer, Boehringer, Dexcom, Eli Lilly, Insulet, Medtronic, Novo Nordisk, Provention Bio, Roche, Sanofi, Ypsomed.	Personal Compensation		
			Click the tab key to add additional rows.		
6	Payment for expert testimony	None     ■			
			Click the tab key to add additional rows.		
7	Support for attending meetings and/or travel	None     ■			
			Click the tab key to add additional rows.		



Continues on the ne				
8	Patents planned, issued or pending	None		
			Click the tab key to add additional rows.	
9	Participation on a Data Safety Monitoring Board or	□ None		
	Advisory Board	Medtronic, Lilly	Personal compensation	
			Click the tab key to add additional rows.	
10	Leadership or fiduciary role in other board, society,	□ None		
	committee or advocacy group, paid or unpaid	SWEET, INNODIA	unpaid	
	8.04p, para 0. arrpara		Click the tab key to add additional rows.	
11	Stock or stock options	□ None		
		DreaMed	Personal	
			Click the tab key to add additional rows.	
12	Receipt of equipment, materials, drugs, medical	⊠ None		
	writing, gifts or other services			
			Click the tab key to add additional rows.	
13	Other financial or non- financial interests	None		
			Click the tab key to add additional rows.	
Please place an "X" next to the following statement to indicate your agreement:				
×	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			